Operating Expenses Summary of Exelixis, Inc.

Exelixis, Inc.'s latest annual operating expenses in 2023 was 1.58 Billion USD , up 17.39% from previous year.
Exelixis, Inc.'s latest quarterly operating expenses in 2024 Q1 was 341.67 Million USD , down -9.16% from previous quarter.
Exelixis, Inc. reported a annual operating expenses of 1.35 Billion USD in annual operating expenses 2022, up 23.39% from previous year.
Exelixis, Inc. reported a annual operating expenses of 1.09 Billion USD in annual operating expenses 2021, up 30.22% from previous year.
Exelixis, Inc. reported a quarterly operating expenses of 1.58 Billion USD for 2023 FY, up 17.39% from previous quarter.
Exelixis, Inc. reported a quarterly operating expenses of 470.72 Million USD for 2023 Q3, up 25.76% from previous quarter.

Annual Operating Expenses Chart of Exelixis, Inc. (2023 - 1998)

Historical Annual Operating Expenses of Exelixis, Inc. (2023 - 1998)

Year	Operating Expenses	Operating Expenses Growth
2023	1.58 Billion USD	17.39%
2022	1.35 Billion USD	23.39%
2021	1.09 Billion USD	30.22%
2020	841.2 Million USD	48.83%
2019	565.2 Million USD	45.44%
2018	388.62 Million USD	43.12%
2017	271.53 Million USD	28.01%
2016	212.11 Million USD	38.04%
2015	153.65 Million USD	-35.96%
2014	239.93 Million USD	4.44%
2013	229.72 Million USD	42.94%
2012	160.71 Million USD	-15.4%
2011	189.96 Million USD	-22.05%
2010	243.69 Million USD	-10.95%
2009	273.66 Million USD	-8.43%
2008	298.85 Million USD	-2.8%
2007	307.45 Million USD	36.39%
2006	225.42 Million USD	32.64%
2005	169.95 Million USD	6.61%
2004	159.4 Million USD	8.53%
2003	146.87 Million USD	11.74%
2002	131.43 Million USD	19.87%
2001	109.64 Million USD	27.17%
2000	86.22 Million USD	146.34%
1999	35 Million USD	99.23%
1998	17.56 Million USD	0.0%

Year	Operating Expenses	Operating Expenses Growth
2024 Q1	341.67 Million USD	-9.16%
2023 FY	1.58 Billion USD	17.39%
2023 Q3	470.72 Million USD	25.76%
2023 Q2	374.29 Million USD	2.37%
2023 Q1	365.64 Million USD	-19.83%
2023 Q4	376.11 Million USD	-20.1%
2022 Q4	456.07 Million USD	45.33%
2022 Q3	313.82 Million USD	-2.61%
2022 Q2	322.24 Million USD	24.16%
2022 Q1	259.53 Million USD	-19.29%
2022 FY	1.35 Billion USD	23.39%
2021 FY	1.09 Billion USD	30.22%
2021 Q3	264.92 Million USD	7.13%
2021 Q2	247.28 Million USD	-5.49%
2021 Q1	261.63 Million USD	10.53%
2021 Q4	321.57 Million USD	21.38%
2020 Q1	164.81 Million USD	8.1%
2020 Q2	174.72 Million USD	6.01%
2020 Q3	264.94 Million USD	51.64%
2020 Q4	236.71 Million USD	-10.65%
2020 FY	841.2 Million USD	48.83%
2019 Q2	140.74 Million USD	14.03%
2019 FY	565.2 Million USD	45.44%
2019 Q4	152.47 Million USD	2.63%
2019 Q3	148.56 Million USD	5.55%
2019 Q1	123.42 Million USD	12.57%
2018 Q1	90.4 Million USD	15.23%
2018 Q4	109.64 Million USD	18.08%
2018 FY	388.62 Million USD	43.12%
2018 Q2	94.34 Million USD	4.36%
2018 Q3	92.86 Million USD	-1.57%
2017 Q3	66.67 Million USD	-3.29%
2017 Q2	68.94 Million USD	19.96%
2017 Q4	78.45 Million USD	17.67%
2017 FY	271.53 Million USD	28.01%
2017 Q1	57.47 Million USD	56.16%
2016 Q4	36.8 Million USD	-30.19%
2016 Q2	58.8 Million USD	-7.8%
2016 Q1	63.78 Million USD	57.04%
2016 Q3	52.71 Million USD	-10.35%
2016 FY	212.11 Million USD	38.04%
2015 Q3	43.93 Million USD	17.8%
2015 Q2	37.29 Million USD	17.23%
2015 Q1	31.81 Million USD	-35.62%
2015 FY	153.65 Million USD	-35.96%
2015 Q4	40.61 Million USD	-7.55%
2014 FY	239.93 Million USD	4.44%
2014 Q4	49.41 Million USD	-7.69%
2014 Q3	53.53 Million USD	-20.62%
2014 Q2	67.44 Million USD	-3.01%
2014 Q1	69.53 Million USD	9.97%
2013 Q3	60.95 Million USD	-2.1%
2013 Q2	62.25 Million USD	43.85%
2013 FY	229.72 Million USD	42.94%
2013 Q1	43.28 Million USD	2.27%
2013 Q4	63.23 Million USD	3.74%
2012 Q4	42.32 Million USD	11.3%
2012 FY	160.71 Million USD	-15.4%
2012 Q1	41 Million USD	8.5%
2012 Q2	39.37 Million USD	-3.98%
2012 Q3	38.02 Million USD	-3.42%
2011 FY	189.96 Million USD	-22.05%
2011 Q1	54.85 Million USD	14.37%
2011 Q2	51.68 Million USD	-5.78%
2011 Q3	45.63 Million USD	-11.7%
2011 Q4	37.78 Million USD	-17.2%
2010 Q4	47.96 Million USD	-17.78%
2010 Q1	73.58 Million USD	-1.07%
2010 FY	243.69 Million USD	-10.95%
2010 Q2	63.8 Million USD	-13.29%
2010 Q3	58.34 Million USD	-8.57%
2009 Q1	62.07 Million USD	-12.02%
2009 Q4	74.38 Million USD	3.6%
2009 Q3	71.79 Million USD	9.75%
2009 Q2	65.41 Million USD	5.38%
2009 FY	273.66 Million USD	-8.43%
2008 Q2	79.09 Million USD	5.94%
2008 Q1	74.66 Million USD	-17.17%
2008 FY	298.85 Million USD	-2.8%
2008 Q4	70.55 Million USD	-5.34%
2008 Q3	74.53 Million USD	-5.77%
2007 Q2	67.56 Million USD	9.87%
2007 Q3	88.25 Million USD	30.64%
2007 Q1	61.49 Million USD	-3.2%
2007 Q4	90.14 Million USD	2.13%
2007 FY	307.45 Million USD	36.39%
2006 Q2	57.62 Million USD	17.18%
2006 Q4	63.52 Million USD	15.29%
2006 Q3	55.1 Million USD	-4.38%
2006 Q1	49.17 Million USD	12.09%
2006 FY	225.42 Million USD	32.64%
2005 Q1	39.83 Million USD	-1.55%
2005 Q4	43.87 Million USD	3.74%
2005 FY	169.95 Million USD	6.61%
2005 Q2	43.95 Million USD	10.34%
2005 Q3	42.29 Million USD	-3.78%
2004 FY	159.4 Million USD	8.53%
2004 Q3	39.3 Million USD	0.04%
2004 Q4	40.46 Million USD	2.96%
2004 Q2	39.28 Million USD	-1.7%
2004 Q1	39.96 Million USD	8.14%
2003 Q4	36.95 Million USD	-0.01%
2003 Q3	36.95 Million USD	-0.97%
2003 Q2	37.32 Million USD	4.73%
2003 Q1	35.63 Million USD	9.02%
2003 FY	146.87 Million USD	11.74%
2002 FY	131.43 Million USD	19.87%
2002 Q4	32.68 Million USD	-2.15%
2002 Q3	33.4 Million USD	1.34%
2002 Q2	32.96 Million USD	4.77%
2002 Q1	31.46 Million USD	-0.24%
2001 Q4	31.54 Million USD	7.93%
2001 FY	109.64 Million USD	27.17%
2001 Q2	26.75 Million USD	12.1%
2001 Q1	23.86 Million USD	6.03%
2001 Q3	29.22 Million USD	9.22%
2000 Q3	21.88 Million USD	-10.84%
2000 FY	86.22 Million USD	146.34%
2000 Q1	17.27 Million USD	0.0%
2000 Q2	24.54 Million USD	42.09%
2000 Q4	22.51 Million USD	2.86%
1999 FY	35 Million USD	99.23%
1998 FY	17.56 Million USD	0.0%

Peer Operating Expenses Comparison of Exelixis, Inc.

Name	Operating Expenses	Operating Expenses Difference
BioNTech SE	2.52 Billion EUR	37.252%
CureVac N.V.	211.75 Million EUR	-649.349%
Biotest Aktiengesellschaft	136.8 Million EUR	-1059.924%
Biotest Aktiengesellschaft	136.8 Million EUR	-1059.924%
BRAIN Biotech AG	24.94 Million EUR	-6262.119%
Formycon AG	23.73 Million EUR	-6585.948%
Heidelberg Pharma AG	27.81 Million EUR	-5604.568%
Medigene AG	20.54 Million EUR	-7625.297%

Global Stocks Search

Exelixis, Inc. (EX9.DE)

Operating Expenses Summary of Exelixis, Inc.

Annual Operating Expenses Chart of Exelixis, Inc. (2023 - 1998)

Historical Annual Operating Expenses of Exelixis, Inc. (2023 - 1998)

Peer Operating Expenses Comparison of Exelixis, Inc.